Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).

Saved in:
Bibliographic Details
Title: Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).
Authors: Morgans AK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Chehrazi-Raffle A; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Niazi T; Division of Radiation Oncology, Department of Oncology, Mcgill University, Montreal, QC, Canada., Shore ND; START carolinas/Carolina Urologic Research Center, Myrtle Beach, SC, USA., Ross AE; Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Røder A; Copenhagen Prostate Cancer Center, Department of Urology, Center for Cancer and Organ Diseases, Copenhagen University Hospital - Rigshospitalet, Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Gomes AJ; Liga Norte Riograndense Contra O Cancer, Natal, Brazil., Supiot S; Department of Radiotherapy, Institut de Cancérologie de l'Ouest, Saint-Herblain, France., Barthélémy P; Medical Oncology Department, University Hospital of Strasbourg, Strasbourg, France., Hatano K; Department of Urology, Graduate School of Medicine, The University of Osaka, Osaka, Japan., Ruiz CBC; Urology and Nephrology Department, Virgen Del Rocío University Hospital, Seville, Spain., Yoshida S; Department of Urology, Institute of Science Tokyo, Tokyo, Japan., Herrera-Imbroda B; Virgen de la Victoria Hospital, Urology Unit, ibima-Plataforma Bionand, Malaga, Spain., Gratton M; Hôpital Hôtel-Dieu de Lévis, Lévis, QC, Canada., Gschwend JE; TUM Klinikum, Rechts der Isar, Technical University Munich, Munich, Germany., Hope TA; Department of Radiology and Biomedical Imaging, University of San Francisco, San Francisco, CA, USA., Joensuu H; Orion Corporation, Orion Pharma, Espoo, Finland., Kuss I; Bayer AG, Berlin, Germany., Le Berre MA; Bayer Healthcare SAS, Lille, France., Dimova-Dobreva M; Bayer Consumer Care AG, Basel, Switzerland., Fizazi K; Centre Oscar Lambret, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.
Source: Future oncology (London, England) [Future Oncol] 2025 Nov; Vol. 21 (27), pp. 3491-3498. Date of Electronic Publication: 2025 Nov 11.
Publication Type: Journal Article; Clinical Trial Protocol
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1744-8301
DOI:10.1080/14796694.2025.2577633